David E. Gerber
University of Texas Southwestern Medical Center
313 Papers
1.3K Citations
David E. Gerber is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Medicine & Lung cancer. The author has an hindex of 45, co-authored 258 publications. Previous affiliations of David E. Gerber include Synthes & University of Washington.
Chat about Author
Papers
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Hossein Borghaei,Luis Paz-Ares,Leora Horn,D. R. Spigel,M. Steins,Neal Ready,L.Q. Chow,Everett E. Vokes,Enriqueta Felip,Esther Holgado,F. Barlesi,M. Kohlhufl,Oscar Arrieta,Marco Angelo Burgio,J. Fayette,H. Lena,Elena Poddubskaya,David E. Gerber,Scott N. Gettinger,Charles M. Rudin,Naiyer A. Rizvi,L. Crina,G. R. Blumenschein,Scott J. Antonia,C. Dorange,C. T. Harbison,F. Graf Finckenstein,Julie R. Brahmer +27 more
TL;DR: Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1, ≥5%, and ≥10%) of the PD-1 ligand.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Matthew D. Hellmann,Naiyer A. Rizvi,Jonathan W. Goldman,Scott N. Gettinger,Hossein Borghaei,Julie R. Brahmer,Neal Ready,David E. Gerber,Laura Qm Chow,Rosalyn A. Juergens,Frances A. Shepherd,Scott A. Laurie,William J. Geese,Shruti Agrawal,Tina C. Young,Xuemei Li,Scott J. Antonia +16 more
TL;DR: The primary outcome was safety and tolerability, assessed in all treated patients, and data from the latter two cohorts, which were considered potentially suitable for further clinical development, are presented.
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Puneeth Iyengar,Zabi Wardak,David E. Gerber,Vasu Tumati,Chul Ahn,Randall S. Hughes,Jonathan E. Dowell,Naga Cheedella,Lucien A. Nedzi,Kenneth D. Westover,Suprabha Pulipparacharuvil,Hak Choy,Robert Timmerman +12 more
TL;DR: Consolidative SAbR prior to maintenance chemotherapy appeared beneficial, nearly tripling PFS in patients with limited metastatic NSCLC compared with maintenance chemotherapy alone, with no difference in toxic effects.
919
Paraneoplastic Syndromes: An Approach to Diagnosis and Treatment
Lorraine Pelosof,David E. Gerber +1 more
- 01 Sep 2010
TL;DR: Because paraneoplastic syndromes often cause considerable morbidity, effective treatment can improve patient quality of life, enhance the delivery of cancer therapy, and prolong survival.
686
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Hossein Borghaei,Scott N. Gettinger,Everett E. Vokes,Laura Q.M. Chow,Marco Angelo Burgio,Javier de Castro Carpeño,Adam Pluzanski,Oscar Arrieta,Osvaldo Arén Frontera,Rita Chiari,Charles Butts,Joanna Wojcik-Tomaszewska,Bruno Coudert,Marina Chiara Garassino,Neal Ready,Enriqueta Felip,Miriam Alonso Garcia,David M. Waterhouse,Manuel Domine,Fabrice Barlesi,Scott J. Antonia,Markus Wohlleber,David E. Gerber,Grzegorz Czyzewicz,David R. Spigel,Lucio Crinò,Wilfried Enst Erich Eberhardt,Ang Li,S. Marimuthu,Julie R. Brahmer +29 more
TL;DR: In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in o... as mentioned in this paper, and showed an improved lung cancer survival.
502